hydrocortisone | 28423-48-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: hydrocortisone
• 英文别名: dihydrocortisone；tetrahydrocortisone；4,5-Dihydrocortisone；(8S,9S,10S,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,4,5,6,7,8,9,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,11-dione
• CAS: 28423-48-5
• 化学式: C₂₁H₃₀O₅
• 分子量: 362.466
• InChiKey: YCLWEYIBFOLMEM-AGIMVQGUSA-N

物化性质

• 熔点：
  233-235 °C
• 沸点：
  543.9±50.0 °C(Predicted)
• 密度：
  1.244±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  91.7
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Sustained-release analgesic compounds
  申请人：——

  公开号：US20030022876A1

  公开（公告）日：2003-01-30

  A pharmaceutically active inventive compound comprises two independently active analgesic moieties covalently conjoined through a physiologically labile linker. A preferred embodiment comprises an opioid, such as morphine, covalently linked to at least one analgesic compound selected from the group consisting of an opioid or a non-opioid compound through a physiologically labile linker. Suitable covalent linkers are covalently bonded to the two independently active analgesic compounds through one or more lactone, lactam, or sulfonamido linkages. Suitable linkers include endogenous carboxylate, amido, and sulfonamido moieties, and exogenous moieties that form the aforementioned lactone, lactam or sulfonamido linkages.

  一种药理活性的创新化合物包括通过生理易降解的连接物共价连接的两个独立活性镇痛基团。一种首选实施例包括阿片类药物，如吗啡，通过生理易降解的连接物与来自阿片类或非阿片类化合物组成的群中选择的至少一种镇痛化合物共价连接。适当的共价连接物通过一个或多个内源的内酯、内酰胺或磺酰胺连接而与这两个独立活性的镇痛化合物共价结合。适当的连接物包括内源的羧酸酯、酰胺和磺酰胺基团，以及形成上述内酯、内酰胺或磺酰胺连接的外源基团。
• [EN] METHOD FOR FLUOROALKYLATION OF ENAMINES<br/>[FR] PROCÉDÉ DE FLUOROALKYLATION D'ÉNAMINES
  申请人：LONZA AG

  公开号：WO2020249759A1

  公开（公告）日：2020-12-17

  The invention discloses a method for fluoroalkylation of enamines with a fluoro alkyl halide in the presence of a base.

  该发明揭示了一种在碱存在下使用氟烷基卤代烃对烯胺进行氟烷基化的方法。
• [EN] HYDROXYMORPHOLINESS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN<br/>[FR] HYDROXYMORPHOLINES ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES ET DE LA DOULEUR
  申请人：BIOCOPEA LTD

  公开号：WO2010103312A1

  公开（公告）日：2010-09-16

  A compound useful for therapy of a pain or inflammatory condition, is of formula (I): wherein: R1 is aryl or heteroaryl and is optionally substituted with one or more groups selected from alkyl, CF3, OR6, OCOR6, CONH2, CN, Cl, Br, I, N(R6)2,NO2, NHCHO, NHCONH2, NHSO2R6, CON(R6)2, S(O)nR6, CH2OH and OCON(R6)2 wherein n is 0-2; R2 and R3 are each H, alkyl, cycloalkyl or CH2 OH, or CR2R3 forms a ring; R4 is H or alkyl; and R6 is H, alkyl or cycloalkyl; or a salt thereof.

  一种用于治疗疼痛或炎症状况的化合物，其化学式为(I)：其中：R1为芳基或杂环芳基，可选择地取代为来自烷基、CF3、OR6、OCOR6、CONH2、CN、Cl、Br、I、N(R6)2、NO2、NHCHO、NHCONH2、NHSO2R6、CON(R6)2、S(O)nR6、CH2OH和OCON(R6)2 的一个或多个基团，其中n为0-2；R2和R3分别为H、烷基、环烷基或CH2OH，或CR2R3形成环；R4为H或烷基；R6为H、烷基或环烷基；或其盐。
• Use of Bupropion Metabolites for the Treatment of Inflammatory Disorders
  申请人：Brew John

  公开号：US20090318562A1

  公开（公告）日：2009-12-24

  Compounds that may be used for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines are of formula (1) or a salt thereof.

  可能用于治疗或预防与T细胞增殖有关或由促炎症细胞因子介导的疾病的化合物为公式（1）或其盐。
• Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain
  申请人：Baxter Andrew Douglas

  公开号：US20100016357A1

  公开（公告）日：2010-01-21

  Compounds that may be used for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines are of formula (I): wherein at least one of R1, R2 or R3 is not H and each is independently H, alkyl, CF 3 , CONH 2 , CN, halogen, NH 2 , NO 2 , NHCHO, NHCONH 2 , NHSO 2 alkyl, SOMe, SO 2 NH 2 , Salkyl, or CH 2 S0 2 alkyl; and R 4 is H or alkyl; or a salt thereof.

  可以用于治疗或预防与T细胞增殖有关或由促炎细胞因子介导的疾病的化合物的公式（I）：其中R1，R2或R3中至少一个不是H，且每个独立地是H，烷基，CF3，CONH2，CN，卤素，NH2，NO2，NHCHO，NHCONH2，NHSO2烷基，SOMe，SO2NH2，S烷基或CH2S02烷基; 而R4为H或烷基; 或其盐。